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SUMMARY  
Dendritic cells (DC) control the type and place of immune responses. Ulcerative colitis 
(UC) is considered a TH2 disease mediated by IL-13 where up to 1/3 of the patients 
can develop extra-intestinal manifestations. Colonic biopsies from inflamed and non-
inflamed areas of UC patients were cultured in vitro and their supernatants were used 
to condition human blood enriched DC from healthy controls. Levels of IL-13 in the 
culture supernatants were below the detection limit in most cases and the cytokine 
profile suggested a mixed profile rather than a TH2 cytokine profile. IL-6 was the 
predominant cytokine found in inflamed areas from UC patients and its concentration 
correlated with the Mayo endoscopic score for severity of disease. DC conditioned with 
non-inflamed areas from UC patients acquired a regulatory phenotype with decreased 
stimulatory capacity. However, DC conditioned with inflamed areas acquired a pro-
inflammatory phenotype, increased expression of skin homing CCR8, did not decrease 
their stimulatory capacity for T-cells and primed them with the skin-homing CLA 
molecule in an IL-6 dependent mechanism. Our results highlight the role of IL-6 in UC 
and question the concept of UC as a TH2 disease and the relevance of IL-13 in its 
aetiology.  
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INTRODUCTION 
The gastrointestinal tract is in contact with a wide variety of commensal microbiota and 
diverse pathogens, and therefore requires a balance to be maintained between 
immunity and immune tolerance; the lack of immune responses, or immune tolerance, 
against food antigens and/or the commensal microbiota is essential to keep the 
homeostasis of the gastrointestinal tract [1]. 
 
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD), traditionally 
related to a TH2 cytokine profile mediated by IL-13 [2, 3], where immune homeostasis 
of the gastro-intestinal tract is compromised. Up to 1/3 of UC patients can develop 
extra-intestinal manifestations being the skin one of such tissues [4, 5]. 
 
Dendritic cells (DC), “commanders-in-chief” of the immune system, are the most potent 
antigen presenting cells. DC determine the nature and type of immune responses [6 7]. 
Intestinal DC control immune tolerance in the gastrointestinal tract [8-10]. DC also 
maintain immune responses localized to specific tissues, where they imprint specific 
tissue-homing profiles on stimulated T-cells [11]. Retinoic acid (RA) (the active form of 
vitamin A following dehydrogenization by the RALDH2 enzyme) controls some of the 
mechanisms of immune homeostasis of the gut [12-14]. RA producing DC mediate the 
IgA switching of B-cells [15], the generation T-cells with regulatory phenotype [10] and 
the imprinting of gut-homing markers on B- and T-cells [16,17], thereby keeping 
tolerogenic immune responses compartimentalized to the gastrointestinal tract. A 
tolerogenic role has also been recently described for fracktalkine (CX3CR1) since 
knockout mice failed to develop oral tolerance [18]. Invariant Vα24 restricted T-cells 
(iNKT cells) also play a role in oral tolerance although their exact role remains unclear 
[19-21]. 
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In healthy individuals, gut microenvironment controls the phenotype and function of 
human DC. Thus, tolerogenic “gut-like” DC can be generated when they are exposed 
to such microenvironment [22-26]. In UC patients immune homeostasis in the gastro-
intestinal tract is compromised. Compared with biopsies from healthy controls, biopsies 
from inflamed and non-inflamed areas of the colon from UC patients exhibit increased 
production of pro-inflammatory cytokines, with higher levels within inflamed areas. 
However the expression of mediators of tissue damage was restricted to inflamed 
areas [27].  
 
We hypothesised that local factors controlling intestinal homeostasis in UC patients are 
either lost or masked by ongoing inflammation in inflamed areas of the gut, driving DC 
towards a pro-inflammatory phenotype, and orchestrating the dysregulated immune 
response in the gut. We characterized the local expression of soluble cytokines and the 
gene expression profile of molecules involved in intestinal homeostasis in the gut. 
Secondly, we studied the effect of conditioning human blood enriched DC with the 
intestinal microenvironment from both inflamed and non-inflamed areas of the gut, from 
UC patients. Our results confirmed that non-inflamed areas of the gut from UC patients 
rendered DC less stimulatory. However, DC conditioned with inflamed areas from the 
same patients acquired an increased production of pro-inflammatory cytokines, a skin-
homing profile and imprinted a skin-homing phenotype on T-cells in an IL-6 dependent 
mechanism.  
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RESULTS 
Increased pro-inflammatory cytokine profile in inflamed areas of UC patients. 
Cells present in biopsies from inflamed areas of UC patients compared with paired 
healthy non-inflamed areas produced higher levels of pro-inflammatory cytokines 
(Figure 1A). Neither gender, nor age nor extension of the disease in the patients 
showed a significant effect on the cytokine production (data not shown). IL-13, 
considered to be the effector cytokine in UC [2,3], was not differentially secreted 
between inflamed and non-inflamed areas of the gut of UC patients and in most of the 
cases (10 out of 11 from healthy and 6 out of 11 from inflamed areas) it was below 
detection limit. IL-13 secretion was also below detection limit in inflamed areas from 2 
of the 3 patients with a Mayo endoscopic score of 3 and therefore it did not correlate 
either with the severity of the disease. IL-6 was the predominant cytokine found in 
inflamed areas of UC patients (2760±813 pg/ml) (Figure 1B) and its concentration 
correlated with the Mayo endoscopic score (Figure 1C) being the only cytokine 
displaying such characteristic. TH2-related cytokines, like IL-4 and IL-7, were also 
increased in inflamed areas. However their low concentration (IL-4: 3.8±0.7 pg/ml; IL-7: 
21.3±3.3 pg/ml) compared with IL-6 (2760±813 pg/ml) and other TH1 related cytokines 
that were also increased in inflamed areas like IFNα, (245.9±27.3 pg/ml), IFNγ 
(328.5±72.63 pg/ml) and TNFα (153.1±36.5 pg/ml) suggest a mixture profile rather 
than a TH2 cytokine profile (Figure 1B). 
 
IL-6 controls the dysregulated cytokine profile in UC patients.  
Since IL-13 is considered to be the effector cytokine in UC [2,3] we performed blocking 
experiments in our culture system. Addition of anti IL-13 to inflamed areas of UC 
patients did not decrease the secretion of any of the assayed cytokines and on the 
contrary it increased further the secretion of IL-4 and IL-17 (Figure 2). These results 
might suggest that in UC patients the role of IL-13 could be elicited through an auto 
and/or paracrine manner which may explain why such cytokine was not found in the 
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culture supernatants (Figure 1A) and therefore why its effect was not abrogated by 
soluble blocking antibody (Figure 2). Addition of soluble recombinant IL-13 to healthy 
intestinal areas of UC patients failed to increase the secretion of IFNγ, TNFα, IL-4 and 
IL-6 as seen on inflamed areas and only restored the secretion of IFNα, IL-7 and IL-17 
(Figure 3). Interestingly, IL-17 was induced both in healthy areas exposed to IL-13 and 
in inflamed areas blocked with anti IL-13 probably reflecting different mechanisms of 
control.  
 
Opposed to IL-13, IL-6 was the predominant cytokine found in the culture supernatants 
of inflamed areas in UC patients (Figure 1B) and its concentration correlated with the 
Mayo endoscopic score (Figure 1C). We explored therefore its role controlling the 
intestinal cytokine milieu in UC patients. Anti IL-6 supplementation to biopsy cultures 
from inflamed areas of UC patients effectively blocked the available IL-6 in the biopsy 
culture supernatants (Figure 4). Secreted cytokines which were up-regulated in 
inflamed areas from UC patients (Figure 1A) were decreased following biopsy 
incubation in the presence of anti IL-6 (Figure 4) and their levels restored (IFNα, TNFα, 
IL-7) or even decreased (IL-4, p<0.01; and IFNγ, p<0.05) compared with those found in 
healthy areas. Similarly, we cultured non-inflamed intestinal areas from UC patients in 
the presence of IL-6. After IL-6 stimulation, all assayed secreted cytokines (except 
regulatory IL-10), were induced in the biopsy cultures (Figure 5) to the levels displayed 
in the paired inflamed areas (Figure 1A) while IFNγ and IL-4 acquired higher values 
than those identified in inflamed areas from such patients (p<0.001 in both cases). 
Together, these findings highlight the central role of soluble IL-6 controlling the 
dysregulated cytokine milieu found in inflamed areas of UC patients in the absence of 
any external challenge and diminish the role of soluble IL-13 in our culture system. 
 
Inflamed areas of the gut from UC patients have decreased expression of 
Cx3CR1 and RALDH2. 
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We then studied the expression of several mRNA molecules related to mechanisms of 
intestinal tolerance, such as bacterial load (16s), Muc2 (main protein from the mucus 
layer), FoxP3 (representative of T-cells with a regulatory phenotype), Vα24 (invariant 
chain of Vα24-restricted invariant NKT cells), Cx3CR1 (fractalkine) and RALDH2 
(necessary to metabolize retinoic acid from dietary vitamin A) (Figure 6). Neither 
gender, nor age nor extension of the disease had any effect in the mRNA expression 
profile of any of the assayed molecules (data not shown). None of the assayed 
molecules correlated with the Mayo endoscopic score for severity of the disease or 
with the concentration of secreted cytokines (data not shown). Muc2, 16s, FoxP3 and 
Vα24 expression were not differentially expressed between sampling areas. However, 
inflamed intestinal areas from UC patients had decreased mRNA expression of both 
RALDH2 and CX3CR1. Having characterized both the local cytokine milieu (Figure 1) 
and the gene expression profile (Figure 6) of both inflamed and non-inflamed areas 
from UC patients, we next studied the effect of such intestinal microenvironment in 
conditioning the phenotype and function of human blood enriched DC.  
 
DC conditioned with inflamed areas of the gut from UC patients become skin-
homing not-regulatory DC. 
DC from each healthy control were conditioned in the presence of basal medium and 
SN from paired healthy and inflamed colonic areas from a single UC patient after 
confirming that this is a valid approach to study the effect of the tissue 
microenvironment on the phenotype and function of DC [26]. Following DC conditioning 
with intestinal microenvironment from inflamed and healthy intestinal areas of UC 
patients, there was no differential cell survival (data not shown). DC conditioned with 
healthy areas from UC patients acquired a regulatory phenotype while those 
conditioned with inflamed areas from the same patients did not. Thus, although 
exposure to both inflamed and healthy areas increased CD40 expression on DC 
together with an increased potential to migrate to the lymph nodes (CCR7 up-
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regulation) (Figures 7A and 7B), HLA-DR expression was specifically decreased in DC 
exposed to non-inflamed areas from the gastrointestinal tract (Figure 7A and 7B). 
Expression of other activation/maturation markers (CD83, CD86) was unaffected, as 
were TLR2 and TLR4 (data not shown). Since CX3CR1 mRNA expression was 
specifically decreased in inflamed areas, we studied expression on DC following 
conditioning with either inflamed or healthy intestinal microenvironments. CX3CR1 
expression on DC was increased on DC exposed to both microenvironments with no 
statistically significant differences (Figure 7A and 7B).  
 
We have previously identified that when cultured “in vitro” in culture medium only, DC 
lose expression of their homing markers [26]. However, if DC are cultured in the 
presence of a tissue microenvironment, DC acquire characteristics of local tissue DC, 
including the expression of specific tissue-associated homing markers. Thus, a gut-
homing profile can be induced on DC when exposed to gut SN from healthy colonic 
biopsies [26]. However DC exposed to gut SN from UC patients (either inflamed or 
healthy areas) did not acquire a gut-homing profile. Thus gut-homing β7 and gut-
retaining CD103 (mean expression below 10% in all cases) were not induced in any 
case. Similarly, the expression of skin-homing markers CLA and CCR4 (mean 
expression below 10% in all cases) did not change either (data not shown). However, 
the skin-homing chemokine receptor CCR8 was specifically induced on DC following 
conditioning with inflamed areas from UC patients (Figures 7A and 7B), providing DC 
with potential to migrate to cutaneous sites.  
 
Non-inflamed areas from UC patients promote a regulatory cytokine phenotype 
on DC. 
Since DC have been cultured with cultured SN that are loaded with cytokines (Figure 
1A), assessing cytokine secretion by DC is not a feasible approach to study their 
cytokine production. Therefore, we studied their natural ongoing intracellular cytokine 
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production following conditioning with intestinal microenvironments. This protocol has 
been validated by our group [8] and allows us to assess the natural on-going cytokine 
production (without external PMA and/or ionomycine stimulus) of DC in the absence of 
any external challenge.  
 
None of the assayed cytokines in the culture SN correlated with the ongoing cytokine 
production of DC following SN-conditioning (data not shown). When exposed to a non-
inflamed microenvironment, DC acquired a regulatory cytokine profile. This was 
demonstrated by the decreased ongoing production of pro-inflammatory cytokines IL-
12 and IL-6, and increased regulatory cytokine IL-10, when compared with DC 
exposed to paired inflamed areas (Figures 8A and 8B). Ongoing production of TGFβ 
was not changed in any case. Therefore, while DC conditioned with healthy SN 
acquired a regulatory cytokine profile, those DC conditioned with inflamed SN from the 
same donors were driven towards a TH1/TH17 cytokine profile.   
 
DC conditioned with inflamed microenvironment increase their stimulatory 
capacity and prime T-cells with a skin-homing profile.  
The stimulatory capacity of DC was specifically modified following SN conditioning 
(Figures 9A and 9B). When total numbers of DC were increased in the mixed leukocyte 
reaction higher T-cell proliferative responses were obtained (Figure 9B). β7 integrin is 
induced in all stimulated human T-cells irrespectively of the source of human DC while 
CLA expression on stimulated T-cells is dependent on the tissue source of human DC 
[26]. DC conditioned with healthy intestinal areas from UC patients decreased their 
stimulatory capacity and promoted the generation of gut-homing T-cells (Figure 9C) 
since stimulated (CFSElow) T-cells maintained gut-homing β7 integrin and decreased 
skin-homing CLA expression compared with un-conditioned (basal) DC. Similar results 
have been previously reported when using culture SN from healthy controls [26]. 
However, when DC had been conditioned with inflamed areas from the same patients, 
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DC did not decrease their stimulatory capacity (Figure 9B). Also, their acquired skin-
homing capacity (Figure 7B) was reflected in an increased capacity to prime skin-
homing CLA on stimulated T-cells compared to DC conditioned with healthy areas from 
the same patients (Figure 9D).  
 
IL-6 plays a central role in the dysregulated immune response in UC patients.  
IL-6 was the predominant cytokine found in inflamed areas from UC patients (Figure 
1B) and its concentration correlated with the Mayo endoscopic score for severity of 
disease in such areas (Figure 1C). Also, natural ongoing production of IL-6 in DC 
correlated with the stimulatory capacity of DC for T-cells (Figure 10A) being the only 
studied cytokine which displayed such characteristics. Therefore we studied the effect 
of IL-6 blocked inflamed supernatants from UC patients, were the cytokine profile was 
restored to normal (Figure 4), on DC phenotype and function. DC conditioned with 
such IL6-blocked microenvironment decreased their stimulatory capacity (Figure 10B); 
generation of stimulated skin-homing T-cells was also inhibited (Figure 10D). To 
confirm that IL-6 controls immune inflammation in UC patients we challenged non-
inflamed areas from such patients with IL-6. Following IL-6 supplementation a pro-
inflammatory cytokine microenvironment was induced (Figure 5) and protective MUC2 
mRNA expression was decreased while Vα24 mRNA expression was increased which 
suggests specific iNKT cell proliferation (data not shown). When blood DC were 
exposed to such an IL-6 rich microenvironment, they decreased their ongoing 
production of IL-10 and failed to decrease their stimulatory capacity (Figure 10C). They 
also acquired the capacity to prime stimulated T-cells with an increased skin homing 
capacity (Figure 10D). Together, our results indicate a central role of human intestinal 
IL-6 in orchestrating immune responses by controlling the pro-inflammatory milieu and 
the subsequent phenotype and function of DC.  
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DISCUSSION 
We have identified that in humans inflamed areas of the gut from UC patients have 
increased production of soluble pro-inflammatory cytokines -where IL-6 was the 
predominant cytokine found in inflamed areas from UC patients- and have decreased 
mRNA expression of RALDH2 and CX3CR1. Such an intestinal microenvironment 
conditions the phenotype and function of blood enriched DC. Non-inflamed areas from 
UC patients biased DC towards a regulatory phenotype with decreased stimulatory 
capacity. Paired DC conditioned with inflamed areas from the same patients increased 
expression of skin homing CCR8, did not decrease their stimulatory capacity and 
primed T-cells with the skin-homing CLA molecule in an IL-6 dependent mechanism. 
Our results question whether UC really is a TH2 based disease and if mirrored in vivo, 
they provide a molecular explanation to the generation of skin extra-intestinal 
manifestations in UC patients.  
 
DC are sentinels and sensors of the immune system and their phenotype and function 
are dependent on the tissue microenvironment [28]. The tissue microenvironment 
confers on DC the capacity to react quickly to the presence of an innate stimulus, also 
activating the mechanisms of a secondary antigen-specific adaptive immune response 
following antigen presentation. If DC are cultured in conditioned-medium which had a 
previous culture of a human tissue and/or a human cell line, DC acquire a tissue-like 
phenotype and express characteristics of resident DC in such a tissue. Thus, human 
gut-like DC can be generated from blood precursors following such a protocol [22-26]. 
Rather than studying the phenotype and function of human tissue DC when the amount 
of tissue is scarce, and therefore functional experiments are not feasible, such 
methodology can be employed to study the effect of tissue microenvironment on 
functions of more readily available blood DC. Following conditioning with tissue 
microenvironment from healthy or inflamed colonic areas from UC patients, DC were 
matured in both cases as assessed by CD40 and CRR7 upregulation (Figure 7). 
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However, and similar to DC conditioned with a colonic microenvironment from healthy 
individuals, DC conditioned with non-inflamed areas from UC patients acquired a 
regulatory or less stimulatory phenotype and T-cell that they stimulated acquired a gut-
homing profile characterized by a decreased CLA expression [26]. On the contrary DC 
conditioned with inflamed areas from UC patients were matured towards a non-
regulatory phenotype since they decreased ongoing production of regulatory IL-10 and 
increased production of pro-inflammatory IL-12 and IL-6 compared to DC conditioned 
with healthy areas from the same patients. Similar observations regarding the capacity 
of intestinal IL-6 to promote immune responses in Crohn’s disease patients have been 
recently described [29]. Future studies should identify the specific mechanisms and 
signalling pathways through which IL-6 mediated effects are established on DC, and 
whether IL-6 on its own (in the absence of an intestinal microenvironment) has the 
capacity to prime DC and/or stimulated T-cells with a skin-homing profile.   
 
Given the dual capacity of DC to control both immunogenic and tolerogenic immune 
responses recent mouse studies have suggested that two different tolerogenic 
(CD103+) and pro-inflammatory (CX3CR1+) non-overlapping DC sub-populations co-
exist in the gut [30-32]. These findings suggest that DC responsible for regulatory and 
inflammatory responses might be of distinct origin, phenotype and function at resting 
and inflammatory conditions. If some circulating contaminating monocytes have 
remained in our blood enriched DC and/or if the same functional dichotomy applies in 
human circulating DC it might be possible that different DC subtypes are involved in 
mediating “regulatory” and “inflammatory” responses in our culture system when 
exposed to different colonic microenvironments. However such studies obtained from 
mouse ileum remain to be validated in the human context and preliminary experiments 
suggest that such separation of populations may not be entirely true in the human 
colon since CX3CR1+ DC are virtually absent from the colonic lamina propria (data not 
shown). On the contrary it seems more feasible that DC phenotype and function are 
Page 57 of 94
Wiley - VCH
European Journal of Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
conditioned by the surrounding microenvironment to perform a tolerogenic or non-
tolerogenic function depending on the required needs. In agreement with our findings, 
intestinal “tolerogenic” antigen presenting cells are reverted towards a pro-
inflammatory phenotype when exposed to an inflamed microenvironment in mice 
models of colitis [33,34]. Therefore, it seems likely that the UC inflamed 
microenvironment will modulate “in vivo” the phenotype of newly arrived DC towards a 
pro-inflammatory phenotype. 
 
Although healthy intestinal areas from UC patients have decreased expression of pro-
inflammatory mediators compared with expression in paired inflamed areas (Figure 
1A), such mediators are still higher than those from biopsies of healthy controls [27]. 
That may explain why DC conditioned with such non-inflamed areas from UC patients 
failed to increase expression of gut-homing markers on DC such as we have described 
when DC are exposed to intestinal culture supernatants form healthy controls [26]. In 
the present manuscript we have also shown that inflamed areas from UC patients had 
decreased mRNA expression of both CX3CR1 and RALDH2 (Figure 6) compared with 
expression in inflamed areas. Although through our approach we do not know in which 
cell type they are expressed, both molecules are essential in mechanisms of intestinal 
homeostasis and oral tolerance [12-14,18]. Whether such decreased expression is a 
consequence of the pro-inflammatory cytokine microenvironment (Figure 1A) or on the 
contrary such pro-inflammatory phenotype is a consequence of decreased CX3CR1 
and/or RALDH2 (among other possible factors) is an issue that has to be answered. 
Neither CX3CR1 nor RALDH2 recovered their normal expression levels in inflamed 
areas in the presence of blocking IL-6. Similarly, they were not decreased in healthy 
areas exposed to IL-6 (data not shown) in spite of the induced pro-inflammatory 
microenvironment (Figure 5). Together, these results suggest that the decreased local 
expression of CX3CR1 and RALDH2 in UC patients may be a pre-disposing factor, 
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rather than a consequence, for local inflammation and tissue damage. However such 
hypothesis should be explored further since some authors have recently described a 
pro-inflammatory role for retinoic acid at low concentrations in the presence of IL-15 
[35]. Also, the role of local iNKT cannot be discarded. Such cell population can display 
both regulatory and pro-inflammatory properties [36] and they have been proposed as 
the original source of pro-inflammatory cytokines in UC [3]. Following IL-6 challenge of 
healthy tissue from UC patients we have identified increased Vα24 expression which 
suggests an iNKT cell expansion. Future studies should define any role for tissue iNKT 
in such pathology.  
 
The causes of extra-intestinal manifestations in IBD are poorly understood and have 
usually been considered as a consequence of a miss-matched immune response of 
the target tissue. However, such extra-intestinal manifestations may be a consequence 
of a dysregulation in the lymphocyte homing pathways [37-39]. In agreement, our 
findings demonstrate the effect of the tissue microenvironment in controlling DC 
phenotype and function, and provide an explanation for the development of extra-
intestinal manifestations in UC patients due to a dysregulated homing response. Thus, 
following conditioning with inflamed areas from UC patients DC acquired a non-
regulatory skin-homing phenotype together with an increased capacity to generate 
skin-homing T-cells through an IL-6 dependent mechanism. Supporting our data, 
aberrant expression of skin homing markers on peripheral blood DC from IBD patients 
suffering from skin manifestations has been recently demonstrated. Also, DC from 
active UC patients increase CLA expression on T-cells that they stimulate (Mann ER, 
personal communications). Future experiments should identify the different nature (if 
any), phenotypic and/or functional particularities of such DC which are likely to be 
involved in the dysregulation of leukocyte trafficking and the development of extra-
intestinal manifestations in IBD.  
 
Page 59 of 94
Wiley - VCH
European Journal of Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
UC has been traditionally considered as a TH2 disease, with IL-13 as the effector 
cytokine [2-3]. Although IL13 mediates damage of intestinal epithelial cells in murine 
models of colitis [40] there is no formal proof that IL-13 is a pathological relevant 
cytokine in UC in humans context since mouse models do not always reflect the exact 
mechanisms and/or cytokine profile found in the human context [3, 41]. Others have 
described a role of IL-13 in human UC pathogenesis characterized as mRNA 
expression in human colonic biopsies [42] or as IL-13 secretion of total lamina propria 
mononuclear cells following an “in vitro” stimulation [2]. Opposed to such studies, our 
assessment of the local cytokine milieu on human samples has been performed in the 
absence of any external stimulus which just measures the spontaneous cytokine 
production and does not support this view in our set of patients. Moreover, inflamed 
and not-inflamed intestinal biopsies from UC patients did not differ regarding 
production of soluble IL-13 and in most cases its concentration was below the limit of 
detection (Figure 1A). Blocking IL-13 in the culture system did not have a major effect 
on the concentration of cytokines in inflamed areas from UC-patients (Figure 2) while 
addition of recombinant IL-13 to healthy intestinal areas (Figure 3) did not have a 
comparable effect in production of pro-inflammatory cytokines to that achieved by IL-6 
stimulation (Figure 5). IL-6 was the predominant cytokine found in inflamed areas from 
UC patients and the subsequent most predominant cytokines were related with a TH1 
profile (Figure 1B). We are aware that the functional potency of secreted cytokines is 
highly dependent on the affinity and density of the specific cytokine receptors and 
therefore a given cytokine might be “ignored” with lower specific receptor densities [43]. 
However, IL-6 also correlated with the Mayo endoscopic score for severity of the 
disease (Figure 1C) while its blockage in inflamed areas reverted the inflammation and 
its supplementation to healthy areas mimicked the inflammation. Together, our data 
questions the relevance of IL-13 and highlights the role of IL-6 in UC such as we and 
others have described [27,44,45] suggesting that UC may be characterized by a 
mixture profile rather than a TH2 cytokine profile [46,47]. Therefore, although current 
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therapies for UC patients involve systemic administration of anti TNFα, anti IL-6 (alone 
and/or in combination with TNFα) is revealed as a potentially more efficient approach 
as some authors have recently reported [48-50].  
 
In summary, our data questions the concept of UC as a TH2 disease, questioning the 
relevance of IL-13 in its etiology and highlighting the role of IL-6 as a central cytokine 
controlling the local immune response. Our results confirmed that the tissue 
microenvironment conditions the phenotype and function of DC. Thus, DC conditioned 
with non-inflamed areas from such patients acquired a tolerogenic “gut-like” phenotype 
with decreased stimulatory capacity. However, DC conditioned with inflamed areas 
from the same patients did not decrease their stimulatory capacity and increased their 
skin-homing phenotype and skin-homing imprinting capacity on T-cells in an IL-6 
dependent mechanism. If mirrored in vivo, this increased potential for skin homing 
provides an explanation for the generation of extra-intestinal manifestations in the skin 
in UC patients and provides us with new targets for immunomodulation.  
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MATERIAL AND METHODS 
Colonic samples and biopsy culture 
Colonic biopsies were obtained at colonoscopy from active UC patients following 
informed consent after ethical approval from the Hospital Clínico Universitario de 
Valladolid (Spain) and the Outer West London Research Ethics Committee (United 
Kingdom). A total of 12 UC patients were sampled. Only one patient had skin extra-
intestinal manifestation of the disease (erythema nodosum) at the time of sample 
taking. Total extension of the lesion and the Mayo endoscopic score (from 0 to 3) for 
severity of the disease were determined for each patient (Table 1). Paired samples 
from the same patient were collected from macroscopically inflamed and 
macroscopically healthy non-inflamed areas of the gut in ice-chilled PBS. Biopsy 
culture was started within an hour. Biopsies were cultured in 1.5ml of complete medium 
(Dutch modified RPMI 1640 (Sigma-Aldrich, Dorset, UK) containing 100u/mL 
penicillin/streptomycin, 2mM L-glutamine, 50µg/mL gentamicine (Sigma-Aldrich) and 
10% foetal calf serum (TCS cellworks, Buckingham, UK) for 24 hours in 12 well culture 
dishes (1 biopsy/well) (37ºC, 5% CO2, high humidity). In some cases, extra biopsies 
from inflamed areas were cultured in the presence of anti IL-6 (0.5µg/ml, R&D) or anti 
IL-13 blocking antibody (2.5µg/ml, R&D) while in others, biopsies from healthy areas 
were cultured in the presence of recombinant IL-6 (50ng/ml, R&D) or IL-13 (50ng/ml, 
R&D). All biopsies had similar size and weight and were randomly cultured in the 
different culture conditions in order to standardize the error in the supernatants´ 
cytokine content which might be derived from different biopsy size. After 24 hours, 
media from biopsy culture were centrifuged and cell-free supernatants (SN) collected, 
while tissue was embedded in RNAlater (Ambion) and snap-frozen. Total RNA was 
isolated from each biopsy using the TRIZOL® reagent according to the protocol 
provided by the manufacturer. Reverse transcription was carried out by using the 
SuperScript® First-Strand Synthesis System for reverse Transcriptase (RT)-PCR Kit 
(Invitrogen, Life Technologies, USA) using random hexamers as primers. 
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Blood samples and biopsy conditioning 
Human peripheral blood was collected from healthy volunteers with no known 
autoimmune or inflammatory diseases, allergies or malignancies, following informed 
consent. Peripheral blood mononuclear cells (PBMC) were obtained by centrifugation 
over Ficoll-Paque Plus (Amersham Biosciences, Chalfont St. Giles, UK). Human blood 
enriched DC were obtained following NycoPrepTM centrifugation of overnight cultured 
PBMC. This protocol has been characterised in detail in previous studies from our 
laboratory as a way to obtain fresh human blood enriched DC [51,52]. Obtained cells 
display morphological characteristics of DC (both at optical microscopy and electron 
microscopy), express HLA-DR and are potent stimulators of naïve T-cells. 
 
DC from each donor were incubated for 24 hours (0.5 million cells/ml) in the presence 
of basal medium and SN from paired healthy and inflamed colonic areas from a single 
UC patient. Such approach provides a tool to study the effect of the intestinal 
microenvironment in the conditioning of the phenotype and function of human DC [26].  
 
Quantitative Polymerase Chain Reaction. 
mRNA levels of 16s, Muc2, FoxP3, Vα24, Cx3CR1, RALDH2 and GADPH 
(housekeeping gene), were measured by real-time PCR by using a LightCycler® 
instrument  (Roche Applied Science, Mannheim, Germany). Reactions were performed 
using the FastStart SYBR Green MasterMix (Roche) with thermolabile Uracil DNA 
Glycosylase (UDG) (Roche) to prevent carry-over contamination. Primer sets and PCR 
conditions are described in table 2. mRNA levels are expressed as the ratio molecule/ 
GADPH in arbitrary units (U). 
  
Cytokines in culture supernatants. 
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Cell-free culture supernatants were analyzed by using a multiplex assay (Biorad, 
Hercules, CA) on a Luminex TM platform (Austin, TX), following the manufacturer´s 
instructions, for the concentration of interferon α (IFNα) [detection limit (D.L.) 125 
pg/ml], IFN gamma (IFNγ [D.L. 4.04 pg/ml], tumour necrosis factor α (TNF-α) [D.L. 3.69 
pg/ml], interleukin (IL)-4 [D.L. 0.43 pg/ml], IL-6 [D.L. 25.7 pg/ml], IL-7 [D.L. 3.18 pg/ml], 
IL-10 [D.L. 1.39 pg/ml], IL-13 [D.L. 3.74 pg/ml] and IL-17 [D.L. 12.63 pg/ml]. Those 
values below the level of detection were reported as being equal to that.  
 
Antibody labelling 
Table 3 shows the specificity, clone and fluorochrome of the monoclonal antibodies 
used. Cells were labelled in PBS containing 1mM EDTA and 0.02% sodium azide 
(FACS buffer). Labelling was performed on ice and in the dark for 20’. Cells were 
washed twice in FACS buffer, fixed with 1% paraformaldehyde in 0.85% saline and 
stored at 40C prior to acquisition on the flow cytometer (within 48 hours). Appropriate 
isotype-matched control antibodies were purchased from the same manufacturers. For 
intracellular staining, cells were fixed with Leucoperm A following surface staining, and 
permeabilized with Leucoperm B before adding antibodies for intracellular labelling. 
The intracellular cytokine production by non-stimulated DC was measured using 
superenhanced Dmax (SED) normalised subtraction (see below) to subtract the normal 
cumulative histogram for cytokine staining with no added monensin from a similar 
histogram of staining with cytokine and added monensin for the last 4 hours of cell 
culture (Sigma, UK). This protocol has been validated by our group [8] and allows us to 
assess the natural on-going cytokine production (without external PMA and/or 
ionomycine stimulus) of DC. After incubation cells were washed in FACS buffer, fixed 
and acquired.  
 
Flow cytometry and data analysis 
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Cells were acquired on a FACSCalibur cytometer (BD Biosciences) and analysed 
using WinList 5.0 software (Verity, ME, US). The proportion of cells positive for a given 
marker was determined by reference to staining with an isotype-matched control 
antibody. For single parameter analysis, WinList was used to subtract the normal 
cumulative histogram for isotype control staining from a similar histogram of staining 
with the test antibody using the superenhanced Dmax (SED) normalised subtraction [53]. 
For multiple parameter analysis positive and negative “gates” were set up, determined 
by reference to staining with isotype-matched control antibodies.  
 
Proliferation assays 
T-cells were obtained from freshly isolated PBMC, and suspended in MiniMACs buffer 
(PBS containing 0.5% BSA and 2mM EDTA). PBMC were depleted of CD14, CD19 
and HLA-DR positive cells with immunomagnetic beads (Miltenyi Biotech, Bisley, UK) 
following manufacturer’s instructions. An average of 94.91%±1.06 (mean±SD) viable T-
cells were obtained following enrichment. T-cells were labelled with CFSE (Invitrogen 
Ltd, UK) following manufacturer’s instructions. Initial CFSE-labelled T-cells (400,000) 
were incubated for 5 days in round-bottomed 96 well microtitre plates (Becton 
Dickinson) with or without different concentrations of allogeneic DC (1%, 2% or 3% of 
T-cells), previously conditioned in a different microenvironment. Cells were recovered 
and percentage and phenotype of stimulated T-cells (CFSElow) were quantified by flow 
cytometry within total CD3+ cells in the lymphogate. Optimization experiments 
confirmed that best proliferation rates with allogeneic CFSE-labelled T-cells were 
obtained at day 5 with no proliferated T-cells before day 4 and with over 80% of the 
cells undergoing cell division after day 7 –data not shown-.  
 
Statistical analyses 
Two-tailed paired t-test, two-tailed Pearson´s correlation and one- or two-way paired 
ANOVA were applied as stated in the figure legends. In the case of multiple 
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comparisons, subsequent ad-hoc Bonferroni correction was applied. The level of 
significance was fixed at p <0.05. 
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FIGURE LEGENDS 
 
FIGURE 1: inflamed areas from UC biopsies have increased pro-inflammatory 
cytokines secretion.  
A) Secretion of soluble cytokines, following 24 hours culture of colonic biopsies, from 
inflamed affected areas of UC patients and paired biopsies from healthy unaffected 
areas from the same patients. B) Cytokine profile in inflamed areas from UC patients, 
and C) correlation between secreted IL-6 from inflamed biopsies and Mayo endoscopic 
score. Paired t-test and Pearson´s correlation were applied respectively. P-value below 
0.05 was considered statistically significant (*p<0.05, **p<0.01). 
 
FIGURE 2: IL-13 blockade has no relevant effect in the cytokine profile of 
inflamed areas from UC patients.  
Biopsies from inflamed areas of UC patients were cultured with and without 2.5µg/ml of 
blocking anti IL-13 and the secretion of soluble cytokines, following 24 hours culture, 
was assayed. Paired t-test was applied. P-value below 0.05 was considered 
statistically significant (*p<0.05, **p<0.01). 
  
FIGURE 3: IL-13 supplementation in healthy areas from UC patients does not 
promote a TH2 microenvironment. 
Biopsies from non-inflamed or healthy areas of UC patients were cultured with and 
without 50ng/ml of recombinant IL-13 and the secretion of soluble cytokines, following 
24 hours culture, was assayed. Paired t-test was applied. P-value below 0.05 was 
considered statistically significant (***p<0.001). 
 
FIGURE 4: IL-6 blockade in inflamed areas from UC patients decreases the pro-
inflammatory microenvironment. 
Biopsies from inflamed areas of UC patients were cultured with and without 0.5µg/ml of 
blocking anti IL-6 and the secretion of soluble cytokines, following 24 hours culture was 
assayed. Paired t-test was applied. P-value below 0.05 was considered statistically 
significant (**p<0.01, ***p<0.001). 
  
FIGURE 5: IL-6 supplementation in healthy areas from UC patients promotes a 
pro-inflammatory microenvironment.  
Biopsies from non-inflamed or healthy areas of UC patients were cultured with and 
without 50ng/ml of recombinant IL-6 and the secretion of soluble cytokines, following 
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24 hours culture assayed. Paired t-test was applied. P-value below 0.05 was 
considered statistically significant (*p<0.05, **p<0.01, ***p<0.0001). 
 
 FIGURE 6: mRNA profile of healthy and inflamed colonic biopsies from UC 
patients. 
mRNA expression, in arbitrary units (U) referred to housekeeping GADPH, in 24 hours 
cultured colonic biopsies from inflamed affected areas of UC patients and paired 
biopsies from healthy unaffected areas, of 16s, MUC2, FOXP3, Vα24, CX3CR1 and 
RALDH2. Paired t-test was applied. P-value below 0.05 was considered statistically 
significant (*p<0.05). 
 
FIGURE 7: Inflamed areas from UC biopsies activate DC 
A) HLA-DR and CD40 intensity ratio (IR) and percentage of CCR7, CX3CR1, and 
CCR8 on blood DC conditioned with colonic biopsy culture supernatant (SN) from 
healthy and inflamed areas of UC patients compared to unconditioned (basal) DC. 
Shaded area represents positive events after subtraction from isotype histograms. 
Each histograms is representative of several independent experiments (HLA-DR, n=12; 
CD40, n=10; CX3CR1, n=12; CCR7, n=11; CCR8, n=7). B) Pool of experiments 
displaying mean±SEM. One way ANOVA repeated measures and paired t-test 
following Bonferroni correction were applied. P-value below 0.05 was considered 
statistically significant (*p<0.05, **p<0.01).  
 
FIGURE 8: DC conditioned with inflamed areas from UC patients fail to acquire a 
regulatory cytokine profile.  
A) Ongoing production of IL-10, IL-12 (p40/p70), IL-6 and TGFβ in DC following 
conditioning with biopsy culture supernatants (SN) from healthy and inflamed areas of 
UC patients compared to unconditioned (basal) DC. Shaded area represents the 
percentage of positive cells following subtraction from paired DC which had been 
incubated in the absence of monensin. Histograms are representative of several 
independent experiments (IL-10, n=11; IL12(p40/p70), n=12; IL-6, n=12; TGFβ, n=12). 
B) Pool of experiments displaying mean±SEM.  One-way ANOVA repeated measures 
and paired t-test following Bonferroni correction were applied. P-value below 0.05 was 
considered statistically significant (*p<0.05).  
 
FIGURE 9: DC conditioned with inflamed areas from UC patients increased their 
stimulatory capacity and prime T-cells with skin-homing capacity 
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A) Percentage of proliferating CFSE-labelled T-cells following 5 days culture alone 
(resting) or in the presence of 3% allogeneic DC which had been previously 
conditioned with culture supernatants (SN) from healthy and inflamed areas from UC 
patients or unconditioned (basal) DC and B) pool of 10 independent paired 
experiments displaying mean±SEM. T-cell proliferative responses were both 
dependent on the doses of DC (p<0.001) and their previous conditioning (p<0.001). 
Healthy-SN conditioned DC were less stimulatory that basal (p<0.01 at 3%) and 
inflamed-conditioned DC (p<0.05 at 2% and p<0.001 at 3%) with no differences among 
the latter. C) β7 (gut-homing) and CLA (skin-homing) dot plots on resting T-cells 
(unconditioned) and T-cells stimulated (CFSElow) by 3% basal, healthy-SN or inflamed-
SN DC and D) pooled data after several independent experiments. Healthy and 
inflamed areas from the same patients where used to condition DC from the same 
healthy donor in all cases. Paired t-test was applied. P-value below 0.05 was 
considered statistically significant (*p<0.05, **p<0.01). 
 
FIGURE 10: IL-6 mediates the increased stimulatory and skin-homing imprinting 
capacity of DC in inflamed areas of UC patients.  
A) Stimulatory capacity of DC on allogeneic T-cells correlates with their IL-6 ongoing 
production. B) and C),  stimulatory capacity of DC on T-cells was dependent on the 
percentage of DC (p<0.001) and their previous conditioning (p<0.001). B) DC 
conditioned with inflamed SN which had been blocked for IL-6 were less stimulatory 
that their unblocked counterparts at 3% (p<0.001, n=10). C) DC conditioned with 
healthy areas from UC patients were less stimulatory than their unconditioned (basal) 
counterparts (p<0.05, n=4). However, if healthy areas had been stimulated with IL-6, 
conditioned DC did not decreased their stimulatory capacity (p<0.01, n=4). D) Pooled 
data after several independent experiments displaying CLA expression on stimulated 
T-cells following culture with stimulated DC. Percentage of divided T-cells and 
phenotype of stimulated T-cells were determined as stated in Figure 9. Pearson´s 
correlation test, two-way ANOVA repeated measures and paired t-test were applied. P-
value below 0.05 was considered statistically significant (*p<0.05, ***p<0.001). 
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Table 1: clinical data of UC patients enrolled in this study. 
Patient Gender Age Mayo endoscopic Score Extension 
1 male 54 2 3 
2 male 29 2 3 
3 male 34 3 2 
4 female 64 3 3 
5 female 51 1 1 
6 male 70 1 2 
7 female 57 3 1 
8 female 65 1 1 
9 female 82 2 2 
10 female 50 1 2 
11 female 66 2 1 
12 male 66 1 2 
Data includes gender, age, Mayo endoscopic score (from 0 to 3) and extension of the 
disease (1: only rectal; 2: lesion affects up to the splenic flexure; 3: lesion passes the 
splenic flexure). 
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Table 2: quantitative PCR primers 
Molecule Primers sequence Ta Primers source 
GADPH Fw 5'-GAAGGTGAAGGTCGGAGTC-3' 60 [54] 
 Rv 5'-GAAGATGGTGATGGGATTTC-3'   
    
16s Fw 5'-TTAAACTCAAAGGAATTGACGG-3' 68 [55] 
 Rv 5'-CTCACGRCACGAGCTGACGAC-3'   
    
FoxP3 Fw 5'-CAGCACATTCCCAGAGTTCCTC-3' 68 [56] 
 Rv 5'-CGCTGTGAACCAGTGGTAGATC-3'   
    
Vα24 Fw 5'-CTGGAGGGAAAGAACTGC-3' 55 [57] 
 Rv 5'-TGTCAGGGAAACAGGACC-3'   
    
MUC2 - 60 Hs00159374_Applied 
    
CX3CR1 - 60 5532957001_Roche 
    
RALDH2 - 60 5532957001_Roche 
Primers used for quantitative PCR including primer sequence, annealing temperature 
(Ta) and primers source. 
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Table 3: Antibodies and flow cytometry 
Antibody Specificity Clone Conjugate Manufacturer 
HLA-DR L243 (G46-6) PECy5 BD Biosciences  
CD40 LOB7/6 FITC AbD Seroter 
CD83 HB15e PE BD Biosciences  
CD86 BU63 PE AbD Serotec 
CX3CR1 528728 PE R&D 
TLR2 TLR2.3 FITC AbD Seroter 
TLR4 HTA125 FITC AbD Seroter 
β7 FIB504 PE BD Biosciences  
β7 FIB504 PECy5 BD Biosciences  
CLA HECA-452 FITC BD Biosciences  
CLA HECA-452 Biotin BD Biosciences  
Streptavidin - APC BD Biosciences  
CD103 Ber-ACT8 FITC BD Biosciences  
CCR4 205410 APC R&D 
CCR10 314315 APC R&D 
CCR7 150503 PE R&D 
IL-6 AS12 FITC BD Biosciences  
IL-10 JES3-19F1 APC BD Biosciences  
IL-12(p40/p70) C11.5 PE BD Biosciences  
TGFβ 35409 PE R&D 
CD3 UCHT1 PeCy5 BD Biosciences  
Specificity, clone, conjugated fluorochrome and manufacturer of the monoclonal 
antibodies used. 
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